Publication Date
| In 2025 | 0 |
| Since 2024 | 0 |
| Since 2021 (last 5 years) | 0 |
| Since 2016 (last 10 years) | 2 |
| Since 2006 (last 20 years) | 9 |
Descriptor
| Outcomes of Treatment | 16 |
| Drug Therapy | 14 |
| Children | 12 |
| Autism | 9 |
| Pervasive Developmental… | 8 |
| Hyperactivity | 7 |
| Attention Deficit Disorders | 5 |
| Behavior Problems | 4 |
| Adolescents | 3 |
| Behavior Disorders | 3 |
| Correlation | 3 |
| More ▼ | |
Source
| Journal of Autism and… | 8 |
| American Journal on Mental… | 2 |
| Autism: The International… | 2 |
| Journal of the American… | 2 |
| Journal of Applied Behavior… | 1 |
| Journal of Intellectual and… | 1 |
Author
Publication Type
| Journal Articles | 16 |
| Reports - Research | 14 |
| Information Analyses | 2 |
| Reports - Evaluative | 2 |
Education Level
| Adult Education | 1 |
Audience
| Researchers | 1 |
Location
Laws, Policies, & Programs
Assessments and Surveys
| Aberrant Behavior Checklist | 2 |
| Social Responsiveness Scale | 1 |
| Vineland Adaptive Behavior… | 1 |
| Wechsler Intelligence Scale… | 1 |
What Works Clearinghouse Rating
Direct linkHardan, Antonio Y.; Hendren, Robert L.; Aman, Michael G.; Robb, Adelaide; Melmed, Raun D.; Andersen, Kristen A.; Luchini, Rachel; Rahman, Rezwanur; Ali, Sanjida; Jia, X Daniel; Mallick, Madhuja; Lateiner, Jordan E.; Palmer, Robert H.; Graham, Stephen M. – Autism: The International Journal of Research and Practice, 2019
Three phase 2 trials were conducted to assess the efficacy and long-term safety of weight-based memantine extended release (ER) treatment in children with autism spectrum disorder. MEM-MD-91, a 50-week open-label trial, identified memantine extended-release treatment responders for enrollment into MEM-MD-68, a 12-week randomized, double-blind,…
Descriptors: Children, Autism, Pervasive Developmental Disorders, Drug Therapy
Lecavalier, Luc; Wood, Jeffrey J.; Halladay, Alycia K.; Jones, Nancy E.; Aman, Michael G.; Cook, Edwin H.; Handen, Benjamin L.; King, Bryan H.; Pearson, Deborah A.; Hallett, Victoria; Sullivan, Katherine Anne; Grondhuis, Sabrina; Bishop, Somer L.; Horrigan, Joseph P.; Dawson, Geraldine; Scahill, Lawrence – Journal of Autism and Developmental Disorders, 2014
Despite the high rate of anxiety in individuals with autism spectrum disorder (ASD), measuring anxiety in ASD is fraught with uncertainty. This is due, in part, to incomplete consensus on the manifestations of anxiety in this population. Autism Speaks assembled a panel of experts to conduct a systematic review of available measures for anxiety in…
Descriptors: Autism, Anxiety, Literature Reviews, Measures (Individuals)
Scahill, Lawrence; Sukhodolsky, Denis G.; Anderberg, Emily; Dimitropoulos, Anastasia; Dziura, James; Aman, Michael G.; McCracken, James; Tierney, Elaine; Hallett, Victoria; Katz, Karol; Vitiello, Benedetto; McDougle, Christopher – Autism: The International Journal of Research and Practice, 2016
Repetitive behavior is a core feature of autism spectrum disorder. We used 8-week data from two federally funded, multi-site, randomized trials with risperidone conducted by the Research Units on Pediatric Psychopharmacology Autism Network to evaluate the sensitivity of the Children's Yale-Brown Obsessive Compulsive Scale modified for autism…
Descriptors: Autism, Pervasive Developmental Disorders, Scores, Networks
Farmer, Cristan; Lecavalier, Luc; Yu, Sunkyung; Arnold, L. Eugene; McDougle, Christopher J.; Scahill, Lawrence; Handen, Benjamin; Johnson, Cynthia R.; Stigler, Kimberly A.; Bearss, Karen; Swiezy, Naomi B.; Aman, Michael G. – Journal of Autism and Developmental Disorders, 2012
The Research Units on Pediatric Psychopharmacology-Autism Network reported additional benefit when adding parent training (PT) to antipsychotic medication in children with autism spectrum disorders and serious behavior problems. The intent-to-treat analyses were rerun with putative predictors and moderators. The "Home Situations…
Descriptors: Behavior Problems, Autism, Hyperactivity, Predictor Variables
Hollway, Jill A.; Aman, Michael G.; Butter, Eric – Journal of Autism and Developmental Disorders, 2013
We explored possible cognitive, behavioral, emotional, and physiological risk markers for sleep disturbance in children with autism spectrum disorders. Data from 1,583 children in the Autism Treatment Network were analyzed. Approximately 45 potential predictors were analyzed using hierarchical regression modeling. As medication could confound…
Descriptors: Correlation, Risk, Autism, Sleep
Handen, Benjamin L.; Melmed, Raun D.; Hansen, Robin L.; Aman, Michael G.; Burnham, David L.; Bruss, Jon B.; McDougle, Christopher J. – Journal of Autism and Developmental Disorders, 2009
Controversy exists regarding the extent and possible causal relationship between gastrointestinal symptoms and autism. A randomized, double-blind, placebo-controlled, parallel groups, dose-ranging study of oral, human immunoglobulin (IGOH 140, 420, or 840 mg/day) was utilized with 125 children (ages 2-17 years) with autism and persistent GI…
Descriptors: Autism, Children, Human Body, Drug Therapy
Lindsay, Ronald L.; Arnold, L. Eugene; Aman, Michael G.; Vitiello, Benedetto; Posey, David J.; McDougle, Christopher J.; Scahill, Lawrence; Pachler, Maryellen; McCracken, James T.; Tierney, Elaine; Bozzolo, Dawn – Journal of Intellectual and Developmental Disability, 2006
Background: Risperidone may be effective in improving tantrums, aggression, or self-injurious behaviour in children with autism, but often leads to weight gain. Method: Using a quantitative Food Frequency Questionnaire (FFQ), we prospectively examined the nutritional intake of 20 children with autism participating in a randomised…
Descriptors: Autism, Nutrition, Behavior Disorders, Children
Aman, Michael G.; And Others – American Journal on Mental Retardation, 1989
The study of effects of haloperidol drug therapy with 20 institutionalized mentally retarded persons found clinical changes confined to a slight reduction in stereotypic behavior and an increase in gross motor activity under the high dose condition. Subjects with high initial levels of stereotypy showed the best response to the drug. (Author/DB)
Descriptors: Behavior Change, Drug Therapy, Effect Size, Institutionalized Persons
And Others; Aman, Michael G. – American Journal on Mental Retardation, 1997
A double-blind, placebo-controlled, crossover study of methylphenidate and different doses of fenfluramine in 30 children (ages 5-14) with mental retardation or borderline IQ and attention deficit hyperactivity disorder was conducted. Parents and teachers cited more improvement with fenfluramine; however, fenfluramine had more side effects,…
Descriptors: Anorexia Nervosa, Attention Deficit Disorders, Children, Drug Therapy
Peer reviewedAman, Michael G.; And Others – Journal of Autism and Developmental Disorders, 1993
Twenty-eight children (ages 5-13) with mental retardation, hyperactivity, and inattentiveness were administered fenfluramine and methylphenidate. Fenfluramine was superior to placebo on the memory task, whereas methylphenidate reduced commission errors on a continuous performance test. Methylphenidate caused shorter response times whereas…
Descriptors: Attention Deficit Disorders, Drug Therapy, Hyperactivity, Memory
Download full textNeef, Nancy A.; Bicard, David F.; Endo, Sayaka; Coury, Daniel L.; Aman, Michael G. – Journal of Applied Behavior Analysis, 2005
We used an assessment that involved competing reinforcer dimensions in a concurrent-schedules arrangement to examine the effects of stimulant medication on impulsivity (i.e., sensitivity of choices to reinforcer immediacy relative to rate, quality, and effort) with 4 students with attention deficit hyperactivity disorder. The assessments were…
Descriptors: Reinforcement, Pharmacology, Stimulants, Hyperactivity
Peer reviewedAman, Michael G.; Langworthy, Kristen S. – Journal of Autism and Developmental Disorders, 2000
A review of 41 studies on pharmacological treatments for children with autism and pervasive personality disorder not otherwise specified, found empirical evidence for significant reductions in hyperactive symptoms was strongest for the antipsychotics, psychostimulants, and naltrexone. A theoretical model is proposed for using attentional…
Descriptors: Attention Deficit Disorders, Attention Span, Children, Drug Therapy
Atomoxetine for Hyperactivity in Autism Spectrum Disorders: Placebo-Controlled Crossover Pilot Trial
Arnold, L. Eugene; Aman, Michael G.; Cook, Amelia M.; Witwer, Andrea N.; Hall, Kristy L.; Thompson, Susan; Ramadan, Yaser – Journal of the American Academy of Child and Adolescent Psychiatry, 2006
Objective: To explore placebo-controlled efficacy and safety of atomoxetine (ATX) for attention-deficit/hyperactivity disorder (ADHD) symptoms in children with autism spectrum disorders (ASD). Method: Children ages 5 to 15 with ASD and prominent ADHD symptoms were randomly assigned to order in a crossover of clinically titrated ATX and placebo, 6…
Descriptors: Hyperactivity, Autism, Drug Therapy, Attention Deficit Disorders
Peer reviewedAman, Michael G.; And Others – Journal of Autism and Developmental Disorders, 1986
The effects of imipramine were assessed in 10 profoundly retarded subjects (aged 8-25 years) who exhibited either depressionlike symptoms or acting out behaviors. Results of observation, interval sampling, and the Aberrant Behavior Checklist indicated behavioral deterioration on irritability, lethargy/social withdrawal, and hyperactivity…
Descriptors: Adults, Behavior Change, Behavior Modification, Children
Peer reviewedAman, Michael G.; White, Anthony J. – Journal of Autism and Developmental Disorders, 1988
Evaluation of 11 moderately/profoundly retarded residents receiving long-term thioridazine treatment found that ratings of hyperactivity and self-injury were significantly lower during the higher dose condition, that high-stereotypy subjects responded better to the drug than low-stereotypy subjects, but that no overall drug effects could be…
Descriptors: Behavior Patterns, Drug Therapy, Hyperactivity, Institutionalized Persons
Previous Page | Next Page ยป
Pages: 1 | 2
